Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TP53TSHR | |
| Ammonia Solution, Strong SCHEMBL18983394 | 0.96 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| SCHEMBL22689331 | 0.96 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Bromide SCHEMBL28542014 | 0.96 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Water SCHEMBL28635166 | 0.96 | ALDH1A1 (0.33) | ALDH1A1TP53TSHR | |
| Ethylene SCHEMBL29034469 | 0.93 | ALDH1A1 (0.32) | ALDH1A1TP53TSHR | |
| SCHEMBL926990 | 0.93 | ALDH1A1 (0.32) | ALDH1A1TP53TSHR | |
| Bicarbonate SCHEMBL15874485 | 0.93 | ALDH1A1 (0.39) | ALDH1A1TP53TSHR | |
| Methylene Chloride SCHEMBL715853 | 0.90 | TSHR (0.30) | ALDH1A1TP53TSHR | |
| Chloroform SCHEMBL28564672 | 0.90 | LMNA (0.30) | ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059366-A1 | RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-118324778-A | Fourth generation EGFR inhibitors | 苏州共康医药科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024140714-A1 | WRN INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140923-A1 | PRMT5-MTA INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024140597-A1 | WRN HELICASE INHIBITOR | 苏州浦合医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118271307-A | PRMT5-MTA inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271322-A | WRN helicase inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271323-A | WRN inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117186093-A | PI3K alpha allosteric inhibitors | 苏州浦合医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117069746-A | Substituted pyrazolopyridines as EGFR inhibitors | 苏州共康医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| CN-1451669-A | Ethylene polymerization and copolymerization catalyst preparing process | TIANDA TIANHAI SCI & TECH DEV (CN) | 2003-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | ALDH1A1 2149/4885TP53 670/4885TSHR 1009/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TP53 1637/4885TSHR 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.